Xilio Therapeutics, Inc.
XLO
$8.95
$0.040.45%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 59.78% | 28.16% | 179.13% | -16.17% | -13.78% |
| Total Depreciation and Amortization | -13.12% | -30.78% | -14.10% | -10.53% | -14.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 50.28% | -170.94% | -1,309.29% | 947.14% | 143.88% |
| Change in Net Operating Assets | -576.47% | -130.01% | 291.55% | -1,022.57% | -108.45% |
| Cash from Operations | -29.60% | -177.10% | 85.89% | -27.96% | -172.56% |
| Capital Expenditure | 95.26% | -2,427.27% | -1,483.33% | 100.00% | -1,809.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 95.26% | -2,427.27% | -1,483.33% | 100.00% | -1,809.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -90.51% | 671.05% | 910.72% | -100.00% | 136.05% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -90.51% | 638.97% | 337.28% | -9,400.00% | 136.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -143.98% | -62.09% | 666.57% | -29.93% | -18.74% |